{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:52:38Z","timestamp":1790787158496,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2003,7,29]],"date-time":"2003-07-29T00:00:00Z","timestamp":1059436800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1038\/sj.bjc.6601155","type":"journal-article","created":{"date-parts":[[2003,7,29]],"date-time":"2003-07-29T13:11:31Z","timestamp":1059484291000},"page":"477-481","source":"Crossref","is-referenced-by-count":100,"title":["Hypersensitivity reactions related to oxaliplatin (OHP)"],"prefix":"10.1038","volume":"89","author":[{"given":"G","family":"Brandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Pantaleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Mordenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Biasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,7,29]]},"reference":[{"key":"BF6601155_CR1","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1200\/JCO.1999.17.11.3560","volume":"17","author":"T Andre'","year":"1999","unstructured":"Andre' T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Dupont-Andre G, De Gramont A (1999) Multicentric phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560\u20133568","journal-title":"J Clin Oncol"},{"key":"BF6601155_CR2","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1200\/JCO.1996.14.11.2950","volume":"14","author":"F Bertheault-Cvitkovic","year":"1996","unstructured":"Bertheault-Cvitkovic F, Jami A, Ithzaki M, Depr\u00e8s Brummer P, Brienza R, Adam R, Kunstlinger F, Bismuth H, Misset JL, Levi F (1996) Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 14: 2950\u20132958","journal-title":"J Clin Oncol"},{"key":"BF6601155_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/jnci\/82.12.1046","volume":"82","author":"JP Caussanel","year":"1990","unstructured":"Caussanel JP, Levi F, Brienza S, Misset JL, Itazhaki M, Adam R, Milano G, Hecquet B, Math\u00e8 Get (1990) Phase II trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046\u20131050","journal-title":"J Natl Cancer Inst"},{"key":"BF6601155_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2222.1976.tb01897.x","volume":"6","author":"MJ Cleare","year":"1976","unstructured":"Cleare MJ, Hughes EG, Jacob B, Pepys B (1976) Immediate (type I) allergic responses to platinum compounds. Clin Allergy 6: 183\u2013195","journal-title":"Clin Allergy"},{"key":"BF6601155_CR5","unstructured":"De Gramont A, Boni C, Navarro M, Tarbenero J, Hickish T, Topham C, Bonetti A, Clingan P, Dvidson N, Mounedji-Boudiaf L, Andr\u00e9 T (2002) Oxaliplatin\/5-FU\/LV in adjuvant colon cancer: safety results of the international randomized MOSAIC Trial. Abstract 525, ASCO 2002"},{"key":"BF6601155_CR6","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A De Gramont","year":"2000","unstructured":"De Gramont A, Figer A, Seynour M, Homerin M, Hmissi A, Cassidy J, Boni C, Corte-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, De Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938\u20132947","journal-title":"J Clin Oncol"},{"key":"BF6601155_CR7","unstructured":"De Gramont A, Maindrault-Goebel F, Louvet C, Andre T, Carola E, Gilles-Amar V, Mabro M, Izrael V, Krulik M (1999) Evaluation of oxaliplatin dose-intensity with the bimonthly 48\u2009h leucovorin (LV) and 5-fluorouracil (5FU) regimens (FOLFOX) in pretreated metastatic colorectal cancer. Proceedings ASCO 1999"},{"key":"BF6601155_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S0959-8049(96)00370-X","volume":"33","author":"A De Gramont","year":"1997","unstructured":"De Gramont A, Vignoud J, Tournigand C, Louvet C, Andr T, Varette C, Raymond E, Moreau S, Le Bail N, Krulik M (1997) Oxaliplatin with high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214\u2013219","journal-title":"Eur J Cancer"},{"key":"BF6601155_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1023\/A:1008200825886","volume":"9","author":"E Diaz-Rubio","year":"1998","unstructured":"Diaz-Rubio E, Sastre J, Zaniboni A, La bianca R, Cort\u00e8s-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9: 105\u2013108","journal-title":"Ann Oncol"},{"key":"BF6601155_CR10","unstructured":"Dold F, Hoey D, Carbery M, Musket A, Friedberg V, Mitchell E (2002) Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Abstract 1478, ASCO 2002"},{"key":"BF6601155_CR11","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1200\/JCO.2002.12.075","volume":"20","author":"A Falcone","year":"2002","unstructured":"Falcone A, Masi G, Allegrini G, Dansei R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P (2002) Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 20: 4006\u20134014","journal-title":"J Clin Oncol"},{"key":"BF6601155_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/JCO.2000.18.1.136","volume":"18","author":"S Giacchetti","year":"2000","unstructured":"Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letornou Y, Coudert B, Bertheault-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III randomized trial of oxaliplatin added to chronomodulated fluorouracil\u2013leucovrin as first line treatment of metastatic colorectal cancer. J Clin Oncol 18: 136\u2013147","journal-title":"J Clin Oncol"},{"key":"BF6601155_CR13","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0140-6736(02)08158-8","volume":"359","author":"S Hetherington","year":"2002","unstructured":"Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowan C, Thurmond LM, Roses AD (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359: 1121\u20131122","journal-title":"Lancet"},{"key":"BF6601155_CR14","first-page":"92","volume":"2","author":"D Hunter","year":"1945","unstructured":"Hunter D, Milton R, Perry KMA (1945) Asthma caused by complex salts of platinum. Br J Ind Med 2: 92\u201398","journal-title":"Br J Ind Med"},{"key":"BF6601155_CR15","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1111\/j.1572-0241.1999.3387a.x","volume":"94","author":"I Larzilliere","year":"1999","unstructured":"Larzilliere I, Brandissou S, Breton P, Lingoungou A, Gargot D, Ramain JP, Harnois C (1999) Anaphylactic reaction to oxaliplatin: a case-report. AJG 94: 3387\u20133388","journal-title":"AJG"},{"key":"BF6601155_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF03258522","volume":"2","author":"F Levi","year":"1994","unstructured":"Levi F, Bourin P, Depr\u00e8-Brummer P, Adam R (1994a) Chronobiology of the immune system. Implication for the delivery of therapeutic agents. Clin Immunother 2: 53\u201364","journal-title":"Clin Immunother"},{"key":"BF6601155_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X","volume":"69","author":"F Levi","year":"1992","unstructured":"Levi F, Misset JL, Brienza S, Adam R, Metzeger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorp-Decler\u00e8 A, Jasmin C, Bismuth H, Reinberg A (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69: 893\u2013900","journal-title":"Cancer"},{"key":"BF6601155_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/0959-8049(93)90073-O","volume":"29","author":"F Levi","year":"1993","unstructured":"Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kurstilnger F, Gastiaburu J, Misset JL (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29: 1280\u20131284","journal-title":"Eur J Cancer"},{"key":"BF6601155_CR19","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1002\/(SICI)1097-0142(19990615)85:12<2532::AID-CNCR7>3.0.CO;2-1","volume":"85","author":"F Levi","year":"1999","unstructured":"Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotsrski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C (1999) A multicentric evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovrin as initial treatment of patients with metastatic colorectal cancer. Cancer 85: 2532\u20132540","journal-title":"Cancer"},{"key":"BF6601155_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","volume":"350","author":"F Levi","year":"1997","unstructured":"Levi F, Zidani R, Misset JL (1997) Randomised multicentric trial of chronotherapy with oxaliplatin, fluorouracil and folinic acid in metastatic colorectal cancer. Lancet 350: 681\u2013686","journal-title":"Lancet"},{"key":"BF6601155_CR21","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","volume":"86","author":"F Levi","year":"1994","unstructured":"Levi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstilnger F, Gastaburu J, Bismuth H, Jasmin C, Misset JL (1994b) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomised multi-institutional trial. J Natl Caner Inst 86: 1608\u20131617","journal-title":"J Natl Caner Inst"},{"key":"BF6601155_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/oxfordjournals.annonc.a010489","volume":"7","author":"D Machover","year":"1996","unstructured":"Machover D, Diaz-Rubio E, De Gramont A, Schilf A, Gastiburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sstre J, Seitz JF, Ychou M (1996) Two consecutive phase II studies of oxaliplatin (l-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95\u201398","journal-title":"Ann Oncol"},{"key":"BF6601155_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S0959-8049(01)00068-5","volume":"37","author":"F Maindrault-Goebel","year":"2001","unstructured":"Maindrault-Goebel F, De Gramont A, Louvet C, Andr\u00e8 T, Carola E, Mabro M, Atru P, Gilles V, Izrael V, Krulik M, for the Oncology Multidisciplanary Research Group (GERCOR 2001) High-dose intensity oxaliplatin added to the simplified bimonthly leucovrin and 5-fluorouracil regimen as second line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 37: 1000\u20131005","journal-title":"Eur J Cancer"},{"key":"BF6601155_CR24","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S0959-8049(99)00149-5","volume":"35","author":"F Maindrault-Goebel","year":"1999","unstructured":"Maindrault-Goebel F, Louvet C, Andr\u00e8 T, Carola E, Lotz JP, Molitor JL, Garcia ML, Giller-Amar V, Izrael V, Krulik M, De Gramont A (1999) Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimens as second-line therapy for metastatic colorectal cancer (FOLFOX-6). Eur J Cancer 35: 1338\u20131342","journal-title":"Eur J Cancer"},{"key":"BF6601155_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belison J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17: 1141\u20131145","journal-title":"J Clin Oncol"},{"key":"BF6601155_CR26","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1023\/A:1026498513593","volume":"10","author":"J Medioni","year":"1999","unstructured":"Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL (1999) Anaphylaxis after oxaliplatin. Ann Oncol 10: 610","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"BF6601155_CR27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/bjc.1998.428","volume":"77","author":"JL Misset","year":"1998","unstructured":"Misset JL (1998) Oxaliplatin in practice. Br J Cancer 77 (Suppl 4): 4\u20137","journal-title":"Br J Cancer"},{"key":"BF6601155_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/annonc\/mdf006","volume":"13","author":"I Monnet","year":"2002","unstructured":"Monnet I, De Cremoux H, Soulie' P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E (2002) Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicentric phase II study. Ann Oncol 13: 103\u2013107","journal-title":"Ann Oncol"},{"issue":"8","key":"BF6601155_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/0959-8049(94)90489-8","volume":"30A","author":"JS Morgan","year":"1994","unstructured":"Morgan JS, Adams M, Mason MD (1994) Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer 30A (8): 1205\u20131206","journal-title":"Eur J Cancer"},{"key":"BF6601155_CR30","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1164\/ajrccm.160.2.9807065","volume":"160","author":"AJ Newman Taylor","year":"1999","unstructured":"Newman Taylor AJ, Cullinan P, Lympany PA, Harris JM, Dowdeswell RJ, DuBois RM (1999) Interaction of HLA phenotype and exposure intensity in sensitization to complex platinum salts. Am J Resp Crit Care Med 160: 435\u2013438","journal-title":"Am J Resp Crit Care Med"},{"key":"BF6601155_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/00000421-199904000-00013","volume":"22","author":"M \u00d6zg\u00fcroglu","year":"1999","unstructured":"\u00d6zg\u00fcroglu M, Demir G, Demirelli F, Mandel NM (1999) Anaphylaxis from intraperitoneal infusion of cisplatin. Am J Clin Oncol 22: 172\u2013173","journal-title":"Am J Clin Oncol"},{"issue":"23","key":"BF6601155_CR32","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1093\/jnci\/83.23.1763-a","volume":"83","author":"RS Planner","year":"1991","unstructured":"Planner RS, Weerasiri T, Timmins D, Grant P (1991) Hypersensitivity reaction to carboplatin. J Natl Cancer 83 (23): 1763\u20131764","journal-title":"J Natl Cancer"},{"key":"BF6601155_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1023\/A:1008366223918","volume":"12","author":"D Santini","year":"2001","unstructured":"Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Dicuonzo G, La Bianca R (2001) Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol 12: 132\u2013133","journal-title":"Ann Oncol"},{"key":"BF6601155_CR34","unstructured":"Seitz JF, Douillard JY, Paillot B (1999) Tomudex (raltitrexed) plus oxaliplatin as fisrt line chemotherapy in metastatic colorectal cancer (MCRC): a promising combination. Abstract 257, ASCO 1999"},{"key":"BF6601155_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF00689458","volume":"35","author":"AA Shleback","year":"1995","unstructured":"Shleback AA, Clark PI, Green JA (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35: 349\u2013351","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF6601155_CR36","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1023\/A:1011161126611","volume":"12","author":"M Stahl","year":"2001","unstructured":"Stahl M, K\u00f6ster W, Wilke H (2001) Reaction after oxaliplatin\u2013prevention with corticosteroids? Ann Oncol 12: 874","journal-title":"Ann Oncol"},{"key":"BF6601155_CR37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/09031936.01.18010243","volume":"18","author":"R Trisolini","year":"2001","unstructured":"Trisolini R, Lazzari Agli L, Tassinari D, Rondelli D, Cancelleri A, Patelli M, Falcone F, Poletti V (2001) Acute lung injury associated with 5-fluorouracil and oxaliplatin combined chemotherapy. Eur Respir J 18: 243\u2013245","journal-title":"Eur Respir J"},{"key":"BF6601155_CR38","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/S0959-8049(98)00064-1","volume":"34","author":"C Tournigand","year":"1998","unstructured":"Tournigand C, Maindrault-Goebel, Louvet C, De Gramont A, Krulik M (1998) Severe anaphylactic reactions of oxaliplatin. Eur J Cancer 34: 1297\u20131298","journal-title":"Eur J Cancer"},{"key":"BF6601155_CR39","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1002\/1097-0142(19940415)73:8<2218::AID-CNCR2820730830>3.0.CO;2-1","volume":"73","author":"B Weideman","year":"1994","unstructured":"Weideman B, M\u00fclleneisen N, Bojko P, Niederle N (1994) Hypersensitivity reactions to carboplatin. Cancer 73: 2218\u20132222","journal-title":"Cancer"},{"key":"BF6601155_CR40","first-page":"219","volume":"63","author":"M Wiesenfeld","year":"1979","unstructured":"Wiesenfeld M, Reiders E, Corder M, Yoo IJ, Lovett J (1979) Successful re-treatment with cis-dichlorodiammineplatinum (II) after apparent allergic reactions. Cancer Treat Rep 63: 219\u2013221","journal-title":"Cancer Treat Rep"},{"key":"BF6601155_CR41","first-page":"458","volume":"19","author":"RB Weiss","year":"1992","unstructured":"Weiss RB (1992) Hypersensitivity reactions. Semin Oncol 19: 458\u2013477","journal-title":"Semin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6601155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601155","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6601155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T05:19:07Z","timestamp":1704863947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6601155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,29]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["BF6601155"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6601155","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,29]]}}}